Advertisement

Chronic Obstructive Pulmonary Disease and Heart Failure

A Breathless Conspiracy

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Peña V.S.
        • Miravitlles M.
        • Gabriel R.
        • et al.
        Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study.
        Chest. 2000; 118: 981-989
        • van Riet E.E.
        • Hoes A.W.
        • Limburg A.
        • et al.
        Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion.
        Eur J Heart Fail. 2014; 16: 772-777
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur J Heart Fail. 2016; 18: 891-975
        • Calzetta L.
        • Rogliani P.
        • Matera M.G.
        • et al.
        A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD.
        Chest. 2016; 149: 1181-1196
        • Holleman Jr., D.R.
        • Simel D.L.
        Does the clinical examination predict airflow limitation?.
        JAMA. 1995; 273: 313-319
        • Pellicori P.
        • Shah P.
        • Cuthbert J.
        • et al.
        Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure.
        Eur J Heart Fail. 2019; https://doi.org/10.1002/ejhf.1383
        • Sze S.
        • Pellicori P.
        • Kamzi S.
        • et al.
        Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure.
        Int J Cardiol. 2018; 264: 104-112
        • Sze S.
        • Pellicori P.
        • Kazmi S.
        • et al.
        Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: a comparison with body mass index.
        JACC Heart Fail. 2018; 6: 476-486
        • Clark A.L.
        • Coats A.J.
        Unreliability of cardiothoracic ratio as a marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography.
        Postgrad Med J. 2000; 76: 289-291
        • Davie A.P.
        • Francis C.M.
        • Love M.P.
        • et al.
        Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction.
        BMJ. 1996; 312: 222
        • Larssen M.S.
        • Steine K.
        • Hilde J.M.
        • et al.
        Mechanisms of ECG signs in chronic obstructive pulmonary disease.
        Open Heart. 2017; 4: e000552
        • Vogelmeier C.F.
        • Criner G.J.
        • Martinez F.J.
        • et al.
        Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary.
        Am J Respir Crit Care Med. 2017; 195: 557-582
        • Woodruff P.G.
        • Barr R.G.
        • Bleecker E.
        • et al.
        • SPIROMICS Research Group
        Clinical significance of symptoms in smokers with preserved pulmonary function.
        N Engl J Med. 2016; 374: 1811-1821
        • Aaron S.D.
        • Tan W.C.
        • Bourbeau J.
        • et al.
        • Canadian Respiratory Research Network
        Diagnostic instability and reversals of chronic obstructive pulmonary disease diagnosis in individuals with mild to moderate airflow obstruction.
        Am J Respir Crit Care Med. 2017; 196: 306-314
        • Perez-Padilla R.
        • Wehrmeister F.C.
        • Montes de Oca M.
        • et al.
        • PLATINO group
        Instability in the COPD diagnosis upon repeat testing vary with the definition of COPD.
        PLoS One. 2015; 10: e0121832
        • Regan E.A.
        • Lynch D.A.
        • Curran-Everett D.
        • et al.
        • Genetic Epidemiology of COPD (COPDGene) Investigators
        Clinical and radiologic disease in smokers with normal spirometry.
        JAMA Intern Med. 2015; 175: 1539-1549
        • Zhang J.
        • Pellicori P.
        • Pan D.
        • et al.
        Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure.
        Int J Cardiol. 2018; 269: 196-200
        • Cleland J.G.
        • Pellicori P.
        Defining diastolic heart failure and identifying effective therapies.
        JAMA. 2013; 309: 825-826
        • Rutten F.H.
        • Cramer M.J.
        • Zuithoff N.P.
        • et al.
        Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease.
        Eur J Heart Fail. 2007; 9: 651-659
        • Watz H.
        • Waschki B.
        • Boehme C.
        • et al.
        Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study.
        Am J Respir Crit Care Med. 2008; 177: 743-751
        • Gale C.P.
        • White J.E.
        • Hunter A.
        • et al.
        Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment.
        J Cardiovasc Med (Hagerstown). 2011; 12: 613-618
        • Macchia A.
        • Rodriguez Moncalvo J.J.
        • Kleinert M.
        • et al.
        Unrecognised ventricular dysfunction in COPD.
        Eur Respir J. 2012; 39: 51-58
        • Pavasini R.
        • Tavazzi G.
        • Biscaglia S.
        • et al.
        Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.
        Chron Respir Dis. 2017; 14: 117-126
        • Hawkins N.M.
        • Khosla A.
        • Virani S.A.
        • et al.
        B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.
        BMC Pulm Med. 2017; 17: 11
        • Adamson P.D.
        • Anderson J.A.
        • Brook R.D.
        • et al.
        Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease.
        J Am Coll Cardiol. 2018; 72: 1126-1137
        • Freixa X.
        • Portillo K.
        • Paré C.
        • et al.
        • PAC-COPD Study Investigators
        Echocardiographic abnormalities in patients with COPD at their first hospital admission.
        Eur Respir J. 2013; 41: 784-791
        • Houben-Wilke S.
        • Spruit M.A.
        • Uszko-Lencer N.H.M.K.
        • et al.
        Echocardiographic abnormalities and their impact on health status in patients with COPD referred for pulmonary rehabilitation.
        Respirology. 2017; 22: 928-934
        • Pellicori P.
        • Cleland J.G.
        • Zhang J.
        • et al.
        Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure.
        Cardiovasc Drugs Ther. 2016; 30: 599-609
        • Divo M.
        • Cote C.
        • de Torres J.P.
        • et al.
        • BODE Collaborative Group
        Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2012; 186: 155-161
        • Cazzola M.
        • Bettoncelli G.
        • Sessa E.
        • et al.
        Prevalence of comorbidities in patients with chronic obstructive pulmonary disease.
        Respiration. 2010; 80: 112-119
        • Curkendall S.M.
        • DeLuise C.
        • Jones J.K.
        • et al.
        Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients.
        Ann Epidemiol. 2006; 16: 63-70
        • Holguin F.
        • Folch E.
        • Redd S.C.
        • et al.
        Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001.
        Chest. 2005; 128: 2005-2011
        • McCullough P.A.
        • Hollander J.E.
        • Nowak R.M.
        • et al.
        • BNP Multinational Study Investigators
        Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department.
        Acad Emerg Med. 2003; 10: 198-204
        • Spece L.J.
        • Epler E.M.
        • Donovan L.M.
        • et al.
        Role of comorbidities in treatment and outcomes after chronic obstructive pulmonary disease exacerbations.
        Ann Am Thorac Soc. 2018; 15: 1033-1038
        • Boudestein L.C.
        • Rutten F.H.
        • Cramer M.J.
        • et al.
        The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease.
        Eur J Heart Fail. 2009; 11: 1182-1188
        • Kaszuba E.
        • Odeberg H.
        • Råstam L.
        • et al.
        Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study.
        BMC Fam Pract. 2018; 19: 178
        • De Blois J.
        • Simard S.
        • Atar D.
        • et al.
        • Norwegian Heart Failure Registry
        COPD predicts mortality in HF: the Norwegian Heart Failure Registry.
        J Card Fail. 2010; 16: 225-229
        • Mentz R.J.
        • Schmidt P.H.
        • Kwasny M.J.
        • et al.
        The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
        J Card Fail. 2012; 18: 515-523
        • Canepa M.
        • Straburzynska-Migaj E.
        • Drozdz J.
        • et al.
        • ESC-HFA Heart Failure Long-Term Registry Investigators
        Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
        Eur J Heart Fail. 2018; 20: 100-110
        • Canepa M.
        • Temporelli P.L.
        • Rossi A.
        • et al.
        • GISSI-HF Investigators
        Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI-HF Trial.
        Cardiology. 2017; 136: 128-137
        • Tavazzi L.
        • Swedberg K.
        • Komajda M.
        • et al.
        • SHIFT Investigators
        Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
        Int J Cardiol. 2013; 170: 182-188
        • Parissis J.T.
        • Andreoli C.
        • Kadoglou N.
        • et al.
        Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.
        Clin Res Cardiol. 2014; 103: 733-741
        • Mentz R.J.
        • Fiuzat M.
        • Wojdyla D.M.
        • et al.
        Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.
        Eur J Heart Fail. 2012; 14: 395-403
        • Cuthbert J.J.
        • Kearsley J.W.
        • Kazmi S.
        • et al.
        The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness.
        Clin Res Cardiol. 2019; 108: 185-193
        • Jacob J.
        • Tost J.
        • Miró Ò.
        • et al.
        • ICA-SEMES Research Group
        Impact of chronic obstructive pulmonary disease on clinical course after an episode of acute heart failure. EAHFE-COPD study.
        Int J Cardiol. 2017; 227: 450-456
        • Iversen K.K.
        • Kjaergaard J.
        • Akkan D.
        • et al.
        • ECHOS Lung Function Study Group
        The prognostic importance of lung function in patients admitted with heart failure.
        Eur J Heart Fail. 2010; 12: 685-691
        • Plesner L.L.
        • Dalsgaard M.
        • Schou M.
        • et al.
        The prognostic significance of lung function in stable heart failure outpatients.
        Clin Cardiol. 2017; 40: 1145-1151
        • Yoshihisa A.
        • Takiguchi M.
        • Shimizu T.
        • et al.
        Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease.
        J Cardiol. 2014; 64: 256-264
        • Pellicori P.
        • Salekin D.
        • Pan D.
        • et al.
        This patient is not breathing properly: is this COPD, heart failure, or neither?.
        Expert Rev Cardiovasc Ther. 2017; 15: 389-396
        • Brenner S.
        • Güder G.
        • Berliner D.
        • et al.
        Airway obstruction in systolic heart failure—COPD or congestion?.
        Int J Cardiol. 2013; 168: 1910-1916
        • Krahnke J.S.
        • Abraham W.T.
        • Adamson P.B.
        • et al.
        • Champion Trial Study Group
        Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device.
        J Card Fail. 2015; 21: 240-249
        • Lawson C.A.
        • Mamas M.A.
        • Jones P.W.
        • et al.
        Association of medication intensity and stages of airflow limitation with the risk of hospitalization or death in patients with heart failure and chronic obstructive pulmonary disease.
        JAMA Netw Open. 2018; 1: e185489
        • Kapoor J.R.
        • Kapoor R.
        • Ju C.
        • et al.
        Precipitating clinical factors, heart failure characterization,and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction.
        JACC Heart Fail. 2016; 4: 464-472
        • Platz E.
        • Jhund P.S.
        • Claggett B.L.
        • et al.
        Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.
        Eur J Heart Fail. 2018; 20: 295-303
        • Arrigo M.
        • Gayat E.
        • Parenica J.
        • et al.
        • GREAT Network
        Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry.
        Eur J Heart Fail. 2017; 19: 201-208
        • Cleland J.G.F.
        • Bunting K.V.
        • Flather M.D.
        • et al.
        • Beta-blockers in Heart Failure Collaborative Group
        Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
        Eur Heart J. 2018; 39: 26-35
        • Hawkins N.M.
        • MacDonald M.R.
        • Petrie M.C.
        • et al.
        Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial.
        Eur J Heart Fail. 2009; 11: 684-690
        • Jabbour A.
        • Macdonald P.S.
        • Keogh A.M.
        • et al.
        Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
        J Am Coll Cardiol. 2010; 55: 1780-1787
        • Düngen H.D.
        • Apostolovic S.
        • Inkrot S.
        • et al.
        • CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure
        Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
        Eur J Heart Fail. 2011; 13: 670-680
        • Sessa M.
        • Mascolo A.
        • Mortensen R.N.
        • et al.
        Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
        Eur J Heart Fail. 2018; 20: 548-556
        • Du Q.
        • Sun Y.
        • Ding N.
        • et al.
        Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.
        PLoS One. 2014; 9: e113048
        • Bhatt S.P.
        • Wells J.M.
        • Kinney G.L.
        • et al.
        • COPDGene Investigators
        β-Blockers are associated with a reduction in COPD exacerbations.
        Thorax. 2016; 71: 8-14
        • Byrd J.B.
        • Newby D.E.
        • Anderson J.A.
        • et al.
        • SUMMIT Investigators
        Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.
        Eur Heart J. 2018; 39: 3128-3134
        • Bhatt S.P.
        • Connett J.E.
        • Voelker H.
        • et al.
        β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol.
        BMJ Open. 2016; 6: e012292
        • Salpeter S.R.
        • Ormiston T.M.
        • Salpeter E.E.
        Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.
        Chest. 2004; 125: 2309-2321
        • Gershon A.
        • Croxford R.
        • Calzavara A.
        • et al.
        Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
        JAMA Intern Med. 2013; 173: 1175-1185
        • Bermingham M.
        • O'Callaghan E.
        • Dawkins I.
        • et al.
        Are beta2 agonists responsible for increased mortality in heart failure?.
        Eur J Heart Fail. 2011; 13: 885-891
        • Oba Y.
        • Keeney E.
        • Ghatehorde N.
        • et al.
        Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
        Cochrane Database Syst Rev. 2018; (CD012620)
        • Ericson-Neilsen W.
        • Kaye A.D.
        Steroids: pharmacology, complications, and practice delivery issues.
        Ochsner J. 2014; 14: 203-207
        • Magnussen H.
        • Disse B.
        • Rodriguez-Roisin R.
        • et al.
        • WISDOM Investigators
        Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
        N Engl J Med. 2014; 371: 1285-1294
        • Chapman K.R.
        • Hurst J.R.
        • Frent S.M.
        • et al.
        Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial.
        Am J Respir Crit Care Med. 2018; 198: 329-339